Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Multi-Center Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Due to Staphylococci

NCT01519492 is registered in ClinicalTrials.gov with Affinium Pharmaceuticals, Ltd as lead sponsor.

NCT NCT01519492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01519492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Multi-Center Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Due to Staphylococci
Lead sponsor
Affinium Pharmaceuticals, Ltd
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2012
Completion date
August 31, 2012
Enrollment
103 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

burn infection, cellulitis, cutaneous abscess, skin and subcutaneous tissue bacterial infections, wound infection